西甲直播

 
公众版
员工版
互联网医院
English
医院首页
医院概况
西甲直播
就诊指南
科室专家
护理天地
健康科普
互联网医院
 
您当前的位置 : 西甲直播  >  肿瘤研究所  >  生化及分子生物学研究室  >  研究生培养
 
研究生导师简介
 时间: 2018-06-13  来源: 西甲直播
 
  

   冯玉梅

  博士,研究员,教授,博士生导师,天津市“131”创新型人才第一层次人选。1983-1987年大学本科就读于于南开大学化学系应用化学专业,1987-1990年硕士研究生就读于南开大学分子生物学研究所生物化学专业,自1990年毕业至今在天津医科大学肿瘤医院肿瘤研究所工作,2003年晋升为研究员,2006年兼聘为教授,2007年遴选为博士研究生导师。自2000年至今任生物化学与分子生物学研究室主任,兼任中国抗癌协会肿瘤标志专业委员会委员(第二、三、四、五届),中国抗癌协会乳腺癌专业委员会委员(第四、五届),天津市细胞生物学会理事(第一、二届),《中国肿瘤临床》杂志编委(第四届)。2004-2005年受天津市教委资助于国外研修,2006-2009年于天津大学在职攻读博士学位。研究方向为肿瘤分子生物学,致力于乳腺癌转移机制研究和肿瘤基因诊断研究。主持国家自然科学基金面上项目5项、天津市自然科学基金重点项目2项、国家“九五”科技攻项目关子课题、国家“863”计划子课题、国家科技支撑计划子课题等;作为第一完成人获天津市自然科学三等奖、天津市科技进步三等奖、天津市卫生局科技成果一等奖、天津医科大学科技成果二等奖各1项;作为通讯作者发表SCI论文20篇,至今他引415次,其中一篇入选全球Top 1% ESI高被引优秀论文;指导博士研究生12名、硕士研究生32名,其中3人获天津医科大学优秀博硕士毕业生、1人获天津医科大学优秀博士论文奖励。主持建设天津医科大学肿瘤医院临床基因扩增(PCR)检验实验室,围绕临床肿瘤个体化诊断和治疗的需求,开展肿瘤相关临床基因诊断项目,为肿瘤发生的病因学诊断、提高肿瘤分期的准确性、评估患者预后、动态监测治疗疗效、预测分子靶向治疗敏感性、指导个体化治疗提供客观依据。

  发表论文(#为共同第一作者,*为通讯作者)

  1. Wang QS, He R, Yang F, Kang LJ, Li XQ, Fu L, Sun B*, Feng YM*. FOXF2 deficiency permits basal-like breast cancer cells to form lymphangiogenic mimicry by enhancing the response of VEGF-C/VEGFR3 signaling pathway. Cancer Lett. 2018, 420:116-126.

  2. Yu ZH#, Lun SM#, He R#, Tian HP, Huang HJ, Wang QS, Li XQ, Feng YM*. Dual Function of MAZ Mediated by FOXF2 in Basal-like Breast Cancer: Promotion of Proliferation and Suppression of Progression. Cancer Lett. 2017, 402:142-152.

  3. Tan CC#, Li GX#, Tan LD, Du X, Li XQ, He R, Wang QS, Feng YM*. Breast cancer cells obtain an osteomimetic feature via epithelial-mesenchymal transition that has undergone BMP2/RUNX2 signaling pathway induction. Oncotarget. 2016, 7(48):79688-79705.

  4. Li XQ, Lu JT, Tan CC, Wang QS, Feng YM*. RUNX2 promotes breast cancer bone metastasis by increasing integrin α5-mediated colonization. Cancer Lett. 2016;380(1):78-86.

  5. Cai J, Tian AX, Wang QS, Kong PZ, Du X, Li XQ, Feng YM*. FOXF2 suppresses the FOXC2-mediated epithelial-mesenchymal transition and multidrug resistance of basal-like breast cancer. Cancer Lett. 2015, 367(2):129-37.

  6. Li XQ, Du X, Li DM, Kong PZ, Sun Y, Liu PF, Wang QS, Feng YM*. ITGBL1 Is a Runx2 Transcriptional Target and Promotes Breast Cancer Bone Metastasis by Activating the TGFβ Signaling Pathway. Cancer Res. 2015, 75(16): 3302-3313.

  7. Tian HP, Lun SM, Huang HJ, He R, Kong PZ, Wang QS, Li XQ, Feng YM*. DNA Methylation Affects the SP1-regulated Transcription of FOXF2 in Breast Cancer Cells. J Biol Chem. 2015;290(31):19173-83.

  8. Wang QS, Kong PZ, Li XQ, Yang F, Feng YM*. FOXF2 deficiency promotes epithelial-mesenchymal transition and metastasis of basal-like breast cancer. Breast Cancer Res. 2015;17:30.

  9. Yu Y, Xiao CH, Tan LD, Wang QS, Li XQ, Feng YM*. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of breast cancer cells through paracrine TGF-β signalling. Br J Cancer. 2014;110(3):724-732.

  10. Yu Y, Wang XY, Sun L, Wang YL, Wan YF, Li XQ, Feng YM*. Inhibition of KIF22 Suppresses Cancer Cell Proliferation by Delaying Mitotic Exit through Up-regulating CDC25C Expression. Carcinogenesis. 2014;35(6):1416-1425.

  11. Du X, Li XQ, Li L, Xu YY, Feng YM*. The detection of ESR1/PGR/ERBB2 mRNA levels by RT-QPCR: a better approach for subtyping breast cancer and predicting prognosis. Breast Cancer Res Treat. 2013;138(1):59-67.

  12. Kong PZ, Yang F, Li L, Li XQ, Feng YM*. Decreased FOXF2 mRNA Expression Indicates Early-Onset Metastasis and Poor Prognosis for Breast Cancer Patients with Histological Grade II Tumor. PLoS One. 2013; 2013;8(4):e61591.

  13. Ge J#, Tian AX#, Wang QS, Kong PZ, Yu Y, Li XQ, Cao XC, Feng YM*. The GSTP1 105Val Allele Increases Breast Cancer Risk and Aggressiveness but Enhances Response to Cyclophosphamide Chemotherapy in North China. PLoS One. 2013;8(6):e67589.

  14. Li XQ, Li L, Xiao CH, Feng YM*. The expression level of NEFL mRNA is a prognostic factor for breast cancer. PLoS One. 2012;7(2):e31146.

  15. Li DM, Feng YM*. Signaling Mechanism of Cell Adhesion Molecules in Breast Cancer Metastasis: Potential Therapeutic Targets. Breast Cancer Res Treat. 2011;128(1):7-21.

  16. Tan LD#, Xu YY#, Yu Y, Li XQ, Chen Y, Feng YM*. Serum HER2 Level Measured by Dot Blot: a Valid and Inexpensive Assay for Monitoring Breast Cancer Progression. PLoS One. 2011;6(4):e18764.

  17. Chen XH, Li XQ, Chen Y, Feng YM*. Risk of Aggressive Breast Cancer in Women of Han Nationality Carrying TGFB1 rs1982073 C Allele and FGFR2 rs1219648 G allele in North China. Breast Cancer Res Treat. 2011;125(2):575-582.

  18. Yu Y, Feng YM*. The Role of Kinesin Family Proteins in Tumorigenesis and Progression: Potential Biomarkers and Molecular Targets for Cancer Therapy. Cancer. 2010;116(22):5150-5160.

  19. Li X, Liu J, Wang Y, Zhang L, Ning L, Feng Y*. Parallel Underexpression of KLK5 and KLK7 mRNA in Breast Malignancies. Cancer Sci. 2009;100(4):601-607.

  20. Li X, Cao X, Li X, Zhang W, Feng Y*. Expression level of insulin-like growth factor binding protein 5 mRNA is a prognostic factor for breast cancer. Cancer Sci. 2007;98(10):1592-1596.

  联系电话:022-23340123转6002

  E-mailfengymei@hotmail.com, ymfeng@tmu.edu.cn

 
 
 
 
法律声明 | 联系我们
Copyright @ 2005 Tianjin Medical University Cancer Institute and Hospital. All rights reserved.
西甲直播(天津医科大学肿瘤医院) 版权所有 津教备0005号 津ICP备05002861号